{"gene":"ALDH7A1","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2010,"finding":"Human ALDH7A1 (antiquitin) catalyzes the NAD+-dependent dehydrogenation of α-aminoadipic semialdehyde (α-AASA), betaine aldehyde (generating the osmolyte betaine), and lipid peroxidation-derived aldehydes (including 4-HNE). Expression of ALDH7A1 in CHO cells attenuated osmotic stress-induced apoptosis. The crystal structure supports these substrate specificities. ALDH7A1 protein was found in the cytosol, nucleus, and mitochondria, with mitochondrial and cytosolic transcripts differentially expressed in a tissue-specific manner in mice.","method":"Recombinant protein enzyme activity assays, crystal structure determination, stable CHO cell expression with viability assays, tissue fractionation/Western blot, cDNA sequence analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted enzymatic activity in vitro, crystal structure, functional cell-based assays, and subcellular fractionation, all in a single rigorous study with multiple orthogonal methods","pmids":["20207735"],"is_preprint":false},{"year":2007,"finding":"Mutations in ALDH7A1 (antiquitin) cause pyridoxine-dependent epilepsy (PDE) by impairing α-AASA dehydrogenase activity in the cerebral lysine degradation pathway. The accumulating intermediate piperideine-6-carboxylate (P6C) inactivates pyridoxal phosphate (PLP) via Knoevenagel condensation, leading to secondary PLP deficiency and seizures. Elevated pipecolic acid and α-AASA in plasma/urine/CSF serve as biomarkers.","method":"Mutational analysis of ALDH7A1 in 18 patients, biochemical measurement of plasma PA and α-AASA, clinical correlation","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 2 / Strong — biochemical mechanism (P6C–PLP Knoevenagel condensation) replicated across multiple patient cohorts and independent labs","pmids":["17068770","20554659","19128417"],"is_preprint":false},{"year":2011,"finding":"Stable expression of mitochondrial ALDH7A1 in CHO cells provides significant protection against lipid peroxidation-derived aldehydes (hexanal and 4-HNE) and hydrogen peroxide cytotoxicity. In vitro enzyme assays show ALDH7A1 is sensitive to oxidative inactivation and can be reactivated by the reducing agent β-mercaptoethanol; reactivated ALDH7A1 metabolizes 4-HNE directly.","method":"Stable CHO cell transfection with viability assays, in vitro recombinant enzyme activity assays with oxidant treatment and β-mercaptoethanol rescue","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro enzyme assay plus cell-based functional assays in single lab, two orthogonal methods","pmids":["21338592"],"is_preprint":false},{"year":2019,"finding":"ALDH7A1 enzymatic activity generates NADH from NAD+; this NADH product targets BARS (Brefeldin-A ADP-Ribosylated Substrate) to inhibit COPI vesicle fission, thereby broadly inhibiting intracellular transport pathways. During hypoxia and starvation, this transport inhibition reduces energy consumption to promote cellular energy homeostasis.","method":"Biochemical assays of COPI vesicle formation, NADH measurement, BARS interaction studies, knockdown/overexpression experiments, energy consumption assays under hypoxia/starvation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic pathway established with multiple orthogonal assays (biochemical reconstitution of COPI inhibition, NADH measurement, genetic manipulation with defined metabolic phenotype)","pmids":["31492851"],"is_preprint":false},{"year":2025,"finding":"ALDH7A1 protects against ferroptosis through two mechanisms: (1) its dehydrogenase activity generates NADH on cellular membranes, which supports FSP1 (ferroptosis suppressor protein 1) activity to reduce lipid peroxidation; (2) it directly consumes reactive aldehydes to decrease lipid peroxidation. Under ferroptotic stress, AMPK is activated and promotes membrane localization of ALDH7A1, which in turn stabilizes FSP1 on membranes.","method":"NADH localization assays, FSP1 activity assays, AMPK activation/inhibition experiments, membrane fractionation, ALDH7A1 knockdown/overexpression with ferroptosis readouts, lipid peroxidation assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal mechanistic methods (enzymatic assays, membrane fractionation, genetic manipulation, pathway epistasis via AMPK), published in high-tier journal with rigorous controls","pmids":["40233740"],"is_preprint":false},{"year":2017,"finding":"Aldh7a1-null zebrafish (generated by CRISPR-Cas9) display spontaneous recurrent seizures with epileptiform electrographic activity, impaired lysine degradation with accumulation of PDE biomarkers (α-AASA, P6C, pipecolic acid), B6 deficiency, and reduced GABA levels. Seizures are rescued by pyridoxine/pyridoxal 5'-phosphate, and lysine supplementation aggravates the phenotype.","method":"CRISPR-Cas9 knockout zebrafish, electroencephalography (tectal recordings), LC-MS/MS metabolite quantification, behavioral assays, pharmacological rescue experiments","journal":"Genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knockout model with multiple biochemical and electrophysiological readouts, replicated by independent CRISPR zebrafish study (PMID 29053735)","pmids":["29061647","29053735"],"is_preprint":false},{"year":1997,"finding":"Human antiquitin (ATQ1/ALDH7A1) is expressed in cochlear outer hair cells (detected by RT-PCR of rat hair cell-specific cDNA), as well as highly in human fetal cochlea, ovary, eye, heart, and kidney. The gene was mapped to human chromosome 5q31 by FISH and mouse chromosome 18 by SSCP mapping.","method":"Northern blot of 13 human fetal tissues, RT-PCR of rat cochlear hair cell-specific cDNA libraries, FISH, SSCP mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct localization by RT-PCR and Northern blot with tissue specificity established, chromosomal mapping confirmed by two methods","pmids":["9417906"],"is_preprint":false},{"year":2014,"finding":"Morpholino knockdown of aldh7a1 in zebrafish causes uveal coloboma and skeletal abnormalities, with reduced cell proliferation in the optic cup. The coloboma phenotype is associated with misregulation of nlz1 (a known coloboma gene), and is partially rescued by co-injection of nlz1 mRNA, placing nlz1 functionally downstream of aldh7a1 in regulating optic cup cell proliferation.","method":"Morpholino knockdown in zebrafish, phenotypic scoring, cell proliferation assays, gene expression analysis, mRNA rescue experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific developmental phenotype and partial pathway epistasis via rescue experiment, single lab","pmids":["25004007"],"is_preprint":false},{"year":2016,"finding":"ALDH7A1 encodes α-aminoadipic semialdehyde dehydrogenase (antiquitin), which converts α-aminoadipic semialdehyde (α-AASA) into α-aminoadipic acid (AAA) as a critical step in brain lysine catabolism. ALDH7A1 dysfunction causes accumulation of α-AASA and P6C; P6C binds and inactivates PLP (the active form of vitamin B6). A novel missense mutation (c.566G>A, p.Gly189Glu) in the NAD+ binding domain of exon 6 was shown to cause neonatal PDE.","method":"Sequence analysis, clinical biochemistry, mutation characterization","journal":"Molecular and cellular probes","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — mutational and biochemical characterization replicated across multiple clinical studies; mechanistic detail of P6C-PLP condensation established in earlier work","pmids":["27856333"],"is_preprint":false}],"current_model":"ALDH7A1 (antiquitin) is a NAD+-dependent aldehyde dehydrogenase localized in the cytosol, nucleus, and mitochondria that catalyzes the oxidation of α-aminoadipic semialdehyde (the rate-limiting step in brain lysine catabolism), betaine aldehyde (generating the osmolyte betaine), and lipid peroxidation-derived aldehydes (e.g., 4-HNE); loss-of-function mutations cause pyridoxine-dependent epilepsy by allowing accumulation of piperideine-6-carboxylate, which inactivates pyridoxal phosphate via Knoevenagel condensation; additionally, the NADH generated by ALDH7A1 activity supports FSP1-mediated ferroptosis suppression on cellular membranes and inhibits COPI-mediated intracellular transport via BARS to conserve energy during hypoxia/starvation, with AMPK-dependent membrane recruitment of ALDH7A1 further stabilizing FSP1 under ferroptotic stress."},"narrative":{"mechanistic_narrative":"ALDH7A1 (antiquitin) is an NAD+-dependent aldehyde dehydrogenase that operates at the intersection of amino acid catabolism, osmotic and oxidative stress defense, and cellular energy homeostasis [PMID:20207735]. It catalyzes the oxidation of α-aminoadipic semialdehyde (α-AASA) — the critical step in brain lysine degradation that produces α-aminoadipic acid — as well as betaine aldehyde (generating the osmolyte betaine) and lipid peroxidation-derived aldehydes such as 4-HNE, and its expression protects cells from osmotic and aldehyde/oxidant cytotoxicity [PMID:20207735, PMID:21338592]. Loss-of-function mutations in ALDH7A1 cause pyridoxine-dependent epilepsy: impaired α-AASA dehydrogenation allows accumulation of piperideine-6-carboxylate (P6C), which inactivates pyridoxal 5'-phosphate by Knoevenagel condensation, producing secondary vitamin B6 deficiency and seizures [PMID:17068770, PMID:20554659, PMID:19128417, PMID:27856333]. This disease mechanism is recapitulated in Aldh7a1-null zebrafish, which show recurrent seizures, PDE biomarker accumulation, reduced GABA, and rescue by pyridoxine/PLP [PMID:29061647, PMID:29053735]. Beyond aldehyde clearance, the NADH product of ALDH7A1 acts as a signaling/metabolic output: it inhibits BARS-dependent COPI vesicle fission to suppress intracellular transport and conserve energy during hypoxia and starvation [PMID:31492851], and it supports FSP1-mediated suppression of ferroptosis on cellular membranes, with AMPK-driven membrane recruitment of ALDH7A1 stabilizing FSP1 under ferroptotic stress [PMID:40233740].","teleology":[{"year":1997,"claim":"Established that antiquitin/ALDH7A1 is a tissue-specifically expressed gene and mapped it to a defined chromosomal locus, providing the molecular handle for later functional and disease work.","evidence":"Northern blot of human fetal tissues, RT-PCR of cochlear hair cell cDNA, FISH and SSCP chromosomal mapping","pmids":["9417906"],"confidence":"Medium","gaps":["No enzymatic activity or substrate assigned at this stage","Functional role in any tissue undefined"]},{"year":2007,"claim":"Resolved why ALDH7A1 mutations cause disease, linking loss of α-AASA dehydrogenase activity to PLP inactivation and seizures rather than a vague metabolic defect.","evidence":"Mutational analysis in 18 patients with biochemical measurement of pipecolic acid and α-AASA and clinical correlation","pmids":["17068770","20554659","19128417"],"confidence":"High","gaps":["P6C–PLP Knoevenagel condensation inferred biochemically rather than structurally resolved in vivo","Did not define the enzyme's full substrate repertoire"]},{"year":2010,"claim":"Defined the enzyme's biochemical identity and substrate breadth, showing ALDH7A1 oxidizes α-AASA, betaine aldehyde, and lipid-peroxidation aldehydes and links to osmotic stress protection.","evidence":"Recombinant enzyme assays, crystal structure, stable CHO expression with viability assays, and subcellular fractionation","pmids":["20207735"],"confidence":"High","gaps":["Physiological relevance of multi-organelle (cytosol/nucleus/mitochondria) localization not dissected","Relative in vivo flux through each substrate unquantified"]},{"year":2011,"claim":"Demonstrated a cytoprotective antioxidant role, showing mitochondrial ALDH7A1 detoxifies reactive aldehydes and is itself redox-regulated through oxidative inactivation/reactivation.","evidence":"Stable CHO transfection viability assays and in vitro enzyme assays with oxidant treatment and β-mercaptoethanol rescue","pmids":["21338592"],"confidence":"Medium","gaps":["Single-lab cell model; in vivo antioxidant contribution not established","Physiological redox switch mechanism not defined"]},{"year":2014,"claim":"Implicated ALDH7A1 in eye/skeletal development beyond metabolism, placing nlz1 functionally downstream in optic cup proliferation.","evidence":"Morpholino knockdown in zebrafish with phenotypic scoring, proliferation assays, and nlz1 mRNA rescue","pmids":["25004007"],"confidence":"Medium","gaps":["Morpholino-based; not confirmed by stable genetic knockout","Molecular link between ALDH7A1 enzymatic activity and nlz1 regulation unknown"]},{"year":2017,"claim":"Provided an in vivo genetic model confirming the lysine-catabolism/B6-deficiency seizure mechanism and demonstrating pharmacological rescue.","evidence":"CRISPR-Cas9 knockout zebrafish with EEG, LC-MS/MS metabolite quantification, behavioral assays, and pyridoxine/PLP rescue; replicated by an independent CRISPR study","pmids":["29061647","29053735"],"confidence":"High","gaps":["Does not address non-metabolic ALDH7A1 functions","Mechanism of GABA reduction downstream of PLP deficiency not fully traced"]},{"year":2019,"claim":"Revealed a signaling role for the enzyme's NADH product, connecting ALDH7A1 activity to suppression of COPI vesicle fission and energy conservation under nutrient/oxygen limitation.","evidence":"COPI vesicle formation assays, NADH measurement, BARS interaction studies, and genetic manipulation with energy-consumption readouts under hypoxia/starvation","pmids":["31492851"],"confidence":"High","gaps":["Direct structural basis of NADH–BARS regulation not resolved","Tissue/physiological contexts where this pathway dominates unclear"]},{"year":2025,"claim":"Extended the NADH-output paradigm to ferroptosis defense, showing AMPK-driven membrane recruitment of ALDH7A1 supports and stabilizes FSP1 while direct aldehyde clearance lowers lipid peroxidation.","evidence":"NADH localization and FSP1 activity assays, AMPK activation/inhibition, membrane fractionation, and ALDH7A1 perturbation with ferroptosis/lipid peroxidation readouts","pmids":["40233740"],"confidence":"High","gaps":["Mechanism of AMPK-dependent membrane targeting of ALDH7A1 not molecularly defined","Relative contribution of NADH-FSP1 axis versus direct aldehyde consumption not quantified"]},{"year":null,"claim":"How ALDH7A1's distinct activities — lysine catabolism, osmolyte/aldehyde detoxification, NADH-driven COPI inhibition, and ferroptosis suppression — are coordinated and partitioned across its cytosolic, nuclear, mitochondrial, and membrane pools remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No integrated model linking subcellular localization to specific functional output","Whether the developmental (coloboma) phenotype reflects metabolic or NADH-signaling functions is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,2]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,8]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[3]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,3,4]}],"complexes":[],"partners":["BARS","FSP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49419","full_name":"Alpha-aminoadipic semialdehyde dehydrogenase","aliases":["Aldehyde dehydrogenase family 7 member A1","Antiquitin-1","Betaine aldehyde dehydrogenase","Delta1-piperideine-6-carboxylate dehydrogenase","P6c dehydrogenase"],"length_aa":539,"mass_kda":58.5,"function":"Aldehyde dehydrogenase enzyme that mediates important protective effects (PubMed:16491085, PubMed:20207735, PubMed:20554659, PubMed:21338592, PubMed:25554827, PubMed:31302938, PubMed:31652343, PubMed:38604394, PubMed:40233740). Protects cells from oxidative stress by metabolizing a number of lipid peroxidation-derived aldehydes (PubMed:16491085, PubMed:20207735, PubMed:21338592, PubMed:40233740). Involved in cellular defense against hyperosmotic stress by metabolizing betaine aldehyde to betaine, an important cellular osmolyte and methyl donor (PubMed:20207735) Involved in lysine catabolism in the brain by mediating the conversion of L-aminoadipate-semialdehyde ((S)-2-amino-6-oxohexanoate) to L-2-aminoadipate Acts as a key inhibitor of ferroptosis both by generating membrane NADH and decreasing the level of reactive aldehydes (PubMed:40233740). Recruited to plasma membrane in response to ferroptotic stress and phosphorylation by AMPK, generating membrane NADH to support AIFM2/FSP1 activity, an essential ferroptosis suppressor protein (PubMed:40233740). Also directly inhibits ferroptosis by decreasing lipid peroxidation via consumption of reactive aldehydes, such as 4-hydroxynonenal (4-HNE) and malonaldehyde (PubMed:40233740). Also acts as a regulator of cellular energy homeostasis in response to cellular energy stress, such as starvation and hypoxia, by inhibiting COPI-mediated intracellular transport, thereby reducing cellular energy consumption (PubMed:31492851)","subcellular_location":"Cytoplasm, cytosol; Cell membrane; Golgi apparatus membrane; Nucleus","url":"https://www.uniprot.org/uniprotkb/P49419/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ALDH7A1","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CD2BP2","stoichiometry":0.2},{"gene":"COPA","stoichiometry":0.2},{"gene":"COPB2","stoichiometry":0.2},{"gene":"COPE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ALDH7A1","total_profiled":1310},"omim":[{"mim_id":"621061","title":"LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT, ATYPICAL; ADLDAT","url":"https://www.omim.org/entry/621061"},{"mim_id":"617290","title":"EPILEPSY, EARLY-ONSET, 1, VITAMIN B6-DEPENDENT; EPEO1","url":"https://www.omim.org/entry/617290"},{"mim_id":"610090","title":"PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD","url":"https://www.omim.org/entry/610090"},{"mim_id":"266100","title":"EPILEPSY, EARLY-ONSET, 4, VITAMIN B6-DEPENDENT; EPEO4","url":"https://www.omim.org/entry/266100"},{"mim_id":"169500","title":"LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT, TYPICAL; ADLDTY","url":"https://www.omim.org/entry/169500"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":151.7}],"url":"https://www.proteinatlas.org/search/ALDH7A1"},"hgnc":{"alias_symbol":["EPD","PDE"],"prev_symbol":["ATQ1"]},"alphafold":{"accession":"P49419","domains":[{"cath_id":"3.40.605.10","chopping":"42-298_508-520","consensus_level":"high","plddt":98.7079,"start":42,"end":520},{"cath_id":"3.40.309.10","chopping":"302-495","consensus_level":"high","plddt":98.5921,"start":302,"end":495}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49419","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49419-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49419-F1-predicted_aligned_error_v6.png","plddt_mean":95.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ALDH7A1","jax_strain_url":"https://www.jax.org/strain/search?query=ALDH7A1"},"sequence":{"accession":"P49419","fasta_url":"https://rest.uniprot.org/uniprotkb/P49419.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49419/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49419"}},"corpus_meta":[{"pmid":"16102838","id":"PMC_16102838","title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.","date":"2005","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16102838","citation_count":702,"is_preprint":false},{"pmid":"22014080","id":"PMC_22014080","title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22014080","citation_count":308,"is_preprint":false},{"pmid":"9184477","id":"PMC_9184477","title":"Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?","date":"1997","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9184477","citation_count":233,"is_preprint":false},{"pmid":"11980706","id":"PMC_11980706","title":"The complex of Arl2-GTP and PDE delta: from structure to function.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11980706","citation_count":192,"is_preprint":false},{"pmid":"20554659","id":"PMC_20554659","title":"Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency).","date":"2010","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20554659","citation_count":190,"is_preprint":false},{"pmid":"15224129","id":"PMC_15224129","title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition.","date":"2004","source":"International journal of impotence research","url":"https://pubmed.ncbi.nlm.nih.gov/15224129","citation_count":184,"is_preprint":false},{"pmid":"14996430","id":"PMC_14996430","title":"L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.","date":"2003","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14996430","citation_count":173,"is_preprint":false},{"pmid":"20207735","id":"PMC_20207735","title":"Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20207735","citation_count":162,"is_preprint":false},{"pmid":"22497841","id":"PMC_22497841","title":"Selective PDE inhibitors as novel treatments for respiratory diseases.","date":"2012","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22497841","citation_count":123,"is_preprint":false},{"pmid":"23193273","id":"PMC_23193273","title":"EPD and EPDnew, high-quality promoter resources in the next-generation sequencing era.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23193273","citation_count":123,"is_preprint":false},{"pmid":"19521983","id":"PMC_19521983","title":"Global and gene-specific promoter methylation changes are related to anti-B[a]PDE-DNA adduct levels and influence micronuclei levels in polycyclic aromatic hydrocarbon-exposed individuals.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19521983","citation_count":119,"is_preprint":false},{"pmid":"17068770","id":"PMC_17068770","title":"Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene.","date":"2007","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17068770","citation_count":117,"is_preprint":false},{"pmid":"7476886","id":"PMC_7476886","title":"Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.","date":"1995","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7476886","citation_count":117,"is_preprint":false},{"pmid":"7589403","id":"PMC_7589403","title":"PDE isoenzymes as targets for anti-asthma drugs.","date":"1995","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/7589403","citation_count":114,"is_preprint":false},{"pmid":"16460876","id":"PMC_16460876","title":"Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate.","date":"2006","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/16460876","citation_count":108,"is_preprint":false},{"pmid":"23721687","id":"PMC_23721687","title":"Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.","date":"2013","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/23721687","citation_count":102,"is_preprint":false},{"pmid":"30117261","id":"PMC_30117261","title":"A patient-derived explant (PDE) model of hormone-dependent cancer.","date":"2018","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30117261","citation_count":99,"is_preprint":false},{"pmid":"31680159","id":"PMC_31680159","title":"EPD in 2020: enhanced data visualization and extension to ncRNA promoters.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31680159","citation_count":85,"is_preprint":false},{"pmid":"30043187","id":"PMC_30043187","title":"The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: A common epileptic encephalopathy.","date":"2019","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/30043187","citation_count":82,"is_preprint":false},{"pmid":"16815627","id":"PMC_16815627","title":"Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.","date":"2006","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/16815627","citation_count":82,"is_preprint":false},{"pmid":"7998974","id":"PMC_7998974","title":"Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions.","date":"1994","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7998974","citation_count":81,"is_preprint":false},{"pmid":"11380813","id":"PMC_11380813","title":"Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition.","date":"2001","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11380813","citation_count":78,"is_preprint":false},{"pmid":"29061647","id":"PMC_29061647","title":"Pyridoxine-Dependent Epilepsy in Zebrafish Caused by Aldh7a1 Deficiency.","date":"2017","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29061647","citation_count":76,"is_preprint":false},{"pmid":"21338592","id":"PMC_21338592","title":"Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity.","date":"2011","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/21338592","citation_count":76,"is_preprint":false},{"pmid":"17933689","id":"PMC_17933689","title":"PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?","date":"2007","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/17933689","citation_count":75,"is_preprint":false},{"pmid":"19128417","id":"PMC_19128417","title":"Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients.","date":"2008","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/19128417","citation_count":64,"is_preprint":false},{"pmid":"14681364","id":"PMC_14681364","title":"The Eukaryotic Promoter Database EPD: the impact of in silico primer extension.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/14681364","citation_count":62,"is_preprint":false},{"pmid":"20030615","id":"PMC_20030615","title":"Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs.","date":"2010","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/20030615","citation_count":59,"is_preprint":false},{"pmid":"17202584","id":"PMC_17202584","title":"Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.","date":"2007","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/17202584","citation_count":59,"is_preprint":false},{"pmid":"25977341","id":"PMC_25977341","title":"PHLPP2 Downregulation Contributes to Lung Carcinogenesis Following B[a]P/B[a]PDE Exposure.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25977341","citation_count":58,"is_preprint":false},{"pmid":"29216750","id":"PMC_29216750","title":"PDE/cAMP/Epac/C/EBP-β Signaling Cascade Regulates Mitochondria Biogenesis of Tubular Epithelial Cells in Renal Fibrosis.","date":"2018","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/29216750","citation_count":53,"is_preprint":false},{"pmid":"25568131","id":"PMC_25568131","title":"PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25568131","citation_count":51,"is_preprint":false},{"pmid":"11607039","id":"PMC_11607039","title":"Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall.","date":"2001","source":"Cardiovascular drug reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11607039","citation_count":51,"is_preprint":false},{"pmid":"25899618","id":"PMC_25899618","title":"Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.","date":"2015","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25899618","citation_count":49,"is_preprint":false},{"pmid":"36500540","id":"PMC_36500540","title":"Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence.","date":"2022","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36500540","citation_count":46,"is_preprint":false},{"pmid":"25464010","id":"PMC_25464010","title":"PDE and cognitive processing: beyond the memory domain.","date":"2014","source":"Neurobiology of learning and memory","url":"https://pubmed.ncbi.nlm.nih.gov/25464010","citation_count":45,"is_preprint":false},{"pmid":"20085380","id":"PMC_20085380","title":"Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.","date":"2010","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/20085380","citation_count":45,"is_preprint":false},{"pmid":"12181425","id":"PMC_12181425","title":"Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo.","date":"2002","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12181425","citation_count":45,"is_preprint":false},{"pmid":"12388409","id":"PMC_12388409","title":"AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.","date":"2002","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388409","citation_count":43,"is_preprint":false},{"pmid":"12836729","id":"PMC_12836729","title":"PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.","date":"2002","source":"Annual review of sex research","url":"https://pubmed.ncbi.nlm.nih.gov/12836729","citation_count":42,"is_preprint":false},{"pmid":"1665311","id":"PMC_1665311","title":"Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.","date":"1991","source":"Agents and actions. Supplements","url":"https://pubmed.ncbi.nlm.nih.gov/1665311","citation_count":42,"is_preprint":false},{"pmid":"8695850","id":"PMC_8695850","title":"Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8695850","citation_count":40,"is_preprint":false},{"pmid":"14559722","id":"PMC_14559722","title":"Prolactin, progesterone, and dexamethasone coordinately and adversely regulate glucokinase and cAMP/PDE cascades in MIN6 beta-cells.","date":"2003","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14559722","citation_count":39,"is_preprint":false},{"pmid":"16956605","id":"PMC_16956605","title":"Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.","date":"2006","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16956605","citation_count":38,"is_preprint":false},{"pmid":"7772058","id":"PMC_7772058","title":"Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected].","date":"1995","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7772058","citation_count":38,"is_preprint":false},{"pmid":"40233740","id":"PMC_40233740","title":"ALDH7A1 protects against ferroptosis by generating membrane NADH and regulating FSP1.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/40233740","citation_count":35,"is_preprint":false},{"pmid":"28859905","id":"PMC_28859905","title":"Atrazine suppresses FSH-induced steroidogenesis and LH-dependent expression of ovulatory genes through PDE-cAMP signaling pathway in human cumulus granulosa cells.","date":"2017","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28859905","citation_count":35,"is_preprint":false},{"pmid":"8387036","id":"PMC_8387036","title":"The role of the cyclic nucleotide phosphodiesterase of Dictyostelium discoideum during growth, aggregation, and morphogenesis: overexpression and localization studies with the separate promoters of the pde.","date":"1993","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8387036","citation_count":35,"is_preprint":false},{"pmid":"9417906","id":"PMC_9417906","title":"An ancient conserved gene expressed in the human inner ear: identification, expression analysis, and chromosomal mapping of human and mouse antiquitin (ATQ1).","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9417906","citation_count":34,"is_preprint":false},{"pmid":"18268925","id":"PMC_18268925","title":"Treating COPD with PDE 4 inhibitors.","date":"2007","source":"International journal of chronic obstructive pulmonary disease","url":"https://pubmed.ncbi.nlm.nih.gov/18268925","citation_count":34,"is_preprint":false},{"pmid":"17433748","id":"PMC_17433748","title":"Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.","date":"2007","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17433748","citation_count":34,"is_preprint":false},{"pmid":"31206508","id":"PMC_31206508","title":"Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology.","date":"2019","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/31206508","citation_count":33,"is_preprint":false},{"pmid":"29053735","id":"PMC_29053735","title":"Characterization of the first knock-out aldh7a1 zebrafish model for pyridoxine-dependent epilepsy using CRISPR-Cas9 technology.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29053735","citation_count":32,"is_preprint":false},{"pmid":"18596129","id":"PMC_18596129","title":"PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.","date":"2008","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/18596129","citation_count":31,"is_preprint":false},{"pmid":"16921490","id":"PMC_16921490","title":"Benzo[a]pyrene diol-epoxide (B[a]PDE) upregulates COX-2 expression through MAPKs/AP-1 and IKKbeta/NF-kappaB in mouse epidermal Cl41 cells.","date":"2007","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16921490","citation_count":31,"is_preprint":false},{"pmid":"28956340","id":"PMC_28956340","title":"PDE Inhibitors for the Treatment of Schizophrenia.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28956340","citation_count":30,"is_preprint":false},{"pmid":"33832760","id":"PMC_33832760","title":"The PDE-Opathies: Diverse Phenotypes Produced by a Functionally Related Multigene Family.","date":"2021","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/33832760","citation_count":30,"is_preprint":false},{"pmid":"28548283","id":"PMC_28548283","title":"Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats.","date":"2017","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28548283","citation_count":30,"is_preprint":false},{"pmid":"16427796","id":"PMC_16427796","title":"Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.","date":"2006","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16427796","citation_count":30,"is_preprint":false},{"pmid":"25229150","id":"PMC_25229150","title":"Active site coupling in PDE:PKA complexes promotes resetting of mammalian cAMP signaling.","date":"2014","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25229150","citation_count":30,"is_preprint":false},{"pmid":"24021351","id":"PMC_24021351","title":"Rutin inhibits B[a]PDE-induced cyclooxygenase-2 expression by targeting EGFR kinase activity.","date":"2013","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24021351","citation_count":29,"is_preprint":false},{"pmid":"25555809","id":"PMC_25555809","title":"An EPD/WSD motifs containing C-type lectin from Argopectens irradians recognizes and binds microbes with broad spectrum.","date":"2014","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25555809","citation_count":28,"is_preprint":false},{"pmid":"28634298","id":"PMC_28634298","title":"Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28634298","citation_count":28,"is_preprint":false},{"pmid":"23647301","id":"PMC_23647301","title":"ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma.","date":"2013","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23647301","citation_count":27,"is_preprint":false},{"pmid":"22018840","id":"PMC_22018840","title":"PDE inhibitors: a new approach to treat metabolic syndrome?","date":"2011","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22018840","citation_count":27,"is_preprint":false},{"pmid":"31492851","id":"PMC_31492851","title":"ALDH7A1 inhibits the intracellular transport pathways during hypoxia and starvation to promote cellular energy homeostasis.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31492851","citation_count":27,"is_preprint":false},{"pmid":"20382846","id":"PMC_20382846","title":"Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20382846","citation_count":27,"is_preprint":false},{"pmid":"26224730","id":"PMC_26224730","title":"Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26224730","citation_count":24,"is_preprint":false},{"pmid":"9515164","id":"PMC_9515164","title":"Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes.","date":"1998","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9515164","citation_count":24,"is_preprint":false},{"pmid":"24664145","id":"PMC_24664145","title":"Clinical diagnosis, treatment, and ALDH7A1 mutations in pyridoxine-dependent epilepsy in three Chinese infants.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24664145","citation_count":24,"is_preprint":false},{"pmid":"30005813","id":"PMC_30005813","title":"Brain malformations associated to Aldh7a1 gene mutations: Report of a novel homozygous mutation and literature review.","date":"2018","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/30005813","citation_count":23,"is_preprint":false},{"pmid":"33500712","id":"PMC_33500712","title":"PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33500712","citation_count":23,"is_preprint":false},{"pmid":"8856432","id":"PMC_8856432","title":"Characterization of DNA polymorphisms in three populations of hereford cattle and their associations with growth and maternal EPD in line 1 herefords.","date":"1996","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/8856432","citation_count":23,"is_preprint":false},{"pmid":"35103832","id":"PMC_35103832","title":"Baicalin attenuates amyloid β oligomers induced memory deficits and mitochondria fragmentation through regulation of PDE-PKA-Drp1 signalling.","date":"2022","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35103832","citation_count":21,"is_preprint":false},{"pmid":"25004007","id":"PMC_25004007","title":"aldh7a1 regulates eye and limb development in zebrafish.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25004007","citation_count":20,"is_preprint":false},{"pmid":"9515168","id":"PMC_9515168","title":"Compartmentalization of PDE-4 and cAMP-dependent protein kinase in neutrophils and macrophages during phagocytosis.","date":"1998","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9515168","citation_count":20,"is_preprint":false},{"pmid":"26276689","id":"PMC_26276689","title":"Parallel Allostery by cAMP and PDE Coordinates Activation and Termination Phases in cAMP Signaling.","date":"2015","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26276689","citation_count":20,"is_preprint":false},{"pmid":"11156556","id":"PMC_11156556","title":"Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries.","date":"2001","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11156556","citation_count":20,"is_preprint":false},{"pmid":"36865908","id":"PMC_36865908","title":"Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36865908","citation_count":19,"is_preprint":false},{"pmid":"10509746","id":"PMC_10509746","title":"Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes.","date":"1999","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10509746","citation_count":19,"is_preprint":false},{"pmid":"27212567","id":"PMC_27212567","title":"A Prospective Case Study of the Safety and Efficacy of Lysine-Restricted Diet and Arginine Supplementation Therapy in a Patient With Pyridoxine-Dependent Epilepsy Caused by Mutations in ALDH7A1.","date":"2016","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27212567","citation_count":19,"is_preprint":false},{"pmid":"36865738","id":"PMC_36865738","title":"cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features.","date":"2023","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/36865738","citation_count":18,"is_preprint":false},{"pmid":"34875337","id":"PMC_34875337","title":"Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line.","date":"2021","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34875337","citation_count":18,"is_preprint":false},{"pmid":"38430382","id":"PMC_38430382","title":"Parameter Identifiability in PDE Models of Fluorescence Recovery After Photobleaching.","date":"2024","source":"Bulletin of mathematical biology","url":"https://pubmed.ncbi.nlm.nih.gov/38430382","citation_count":17,"is_preprint":false},{"pmid":"38158096","id":"PMC_38158096","title":"Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38158096","citation_count":17,"is_preprint":false},{"pmid":"31660837","id":"PMC_31660837","title":"A Mechanistic Rationale for PDE-4 Inhibitors to Treat Residual Cognitive Deficits in Acquired Brain Injury.","date":"2020","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31660837","citation_count":17,"is_preprint":false},{"pmid":"32791334","id":"PMC_32791334","title":"Moderate treadmill exercise improves spatial learning and memory deficits possibly via changing PDE-5, IL-1 β and pCREB expression.","date":"2020","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/32791334","citation_count":17,"is_preprint":false},{"pmid":"32102361","id":"PMC_32102361","title":"In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32102361","citation_count":17,"is_preprint":false},{"pmid":"35629230","id":"PMC_35629230","title":"A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35629230","citation_count":17,"is_preprint":false},{"pmid":"24136683","id":"PMC_24136683","title":"The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.","date":"2013","source":"Current urology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24136683","citation_count":17,"is_preprint":false},{"pmid":"21501596","id":"PMC_21501596","title":"Cyanidin-3-glucoside suppresses B[a]PDE-induced cyclooxygenase-2 expression by directly inhibiting Fyn kinase activity.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21501596","citation_count":16,"is_preprint":false},{"pmid":"15254413","id":"PMC_15254413","title":"Unraveling genes and pathways influenced by H-prune PDE overexpression: a model to study cellular motility.","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15254413","citation_count":16,"is_preprint":false},{"pmid":"9631240","id":"PMC_9631240","title":"Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).","date":"1998","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9631240","citation_count":15,"is_preprint":false},{"pmid":"24222327","id":"PMC_24222327","title":"Tehranolide inhibits cell proliferation via calmodulin inhibition, PDE, and PKA activation.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24222327","citation_count":15,"is_preprint":false},{"pmid":"23376216","id":"PMC_23376216","title":"Pyridoxine-dependent epilepsy in Tunisia is caused by a founder missense mutation of the ALDH7A1 gene.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23376216","citation_count":15,"is_preprint":false},{"pmid":"25907439","id":"PMC_25907439","title":"Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.","date":"2015","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/25907439","citation_count":15,"is_preprint":false},{"pmid":"37175842","id":"PMC_37175842","title":"Unleashing Spinal Cord Repair: The Role of cAMP-Specific PDE Inhibition in Attenuating Neuroinflammation and Boosting Regeneration after Traumatic Spinal Cord Injury.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37175842","citation_count":15,"is_preprint":false},{"pmid":"33713531","id":"PMC_33713531","title":"H2 S catalysed by CBS regulates testosterone synthesis through affecting the sulfhydrylation of PDE.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33713531","citation_count":15,"is_preprint":false},{"pmid":"27856333","id":"PMC_27856333","title":"Novel homozygous missense mutation in ALDH7A1 causes neonatal pyridoxine dependent epilepsy.","date":"2016","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/27856333","citation_count":14,"is_preprint":false},{"pmid":"9631239","id":"PMC_9631239","title":"Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure.","date":"1998","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/9631239","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51932,"output_tokens":2780,"usd":0.098748,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10183,"output_tokens":3296,"usd":0.066657,"stage2_stop_reason":"end_turn"},"total_usd":0.165405,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"Human ALDH7A1 (antiquitin) catalyzes the NAD+-dependent dehydrogenation of α-aminoadipic semialdehyde (α-AASA), betaine aldehyde (generating the osmolyte betaine), and lipid peroxidation-derived aldehydes (including 4-HNE). Expression of ALDH7A1 in CHO cells attenuated osmotic stress-induced apoptosis. The crystal structure supports these substrate specificities. ALDH7A1 protein was found in the cytosol, nucleus, and mitochondria, with mitochondrial and cytosolic transcripts differentially expressed in a tissue-specific manner in mice.\",\n      \"method\": \"Recombinant protein enzyme activity assays, crystal structure determination, stable CHO cell expression with viability assays, tissue fractionation/Western blot, cDNA sequence analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted enzymatic activity in vitro, crystal structure, functional cell-based assays, and subcellular fractionation, all in a single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"20207735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mutations in ALDH7A1 (antiquitin) cause pyridoxine-dependent epilepsy (PDE) by impairing α-AASA dehydrogenase activity in the cerebral lysine degradation pathway. The accumulating intermediate piperideine-6-carboxylate (P6C) inactivates pyridoxal phosphate (PLP) via Knoevenagel condensation, leading to secondary PLP deficiency and seizures. Elevated pipecolic acid and α-AASA in plasma/urine/CSF serve as biomarkers.\",\n      \"method\": \"Mutational analysis of ALDH7A1 in 18 patients, biochemical measurement of plasma PA and α-AASA, clinical correlation\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — biochemical mechanism (P6C–PLP Knoevenagel condensation) replicated across multiple patient cohorts and independent labs\",\n      \"pmids\": [\"17068770\", \"20554659\", \"19128417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Stable expression of mitochondrial ALDH7A1 in CHO cells provides significant protection against lipid peroxidation-derived aldehydes (hexanal and 4-HNE) and hydrogen peroxide cytotoxicity. In vitro enzyme assays show ALDH7A1 is sensitive to oxidative inactivation and can be reactivated by the reducing agent β-mercaptoethanol; reactivated ALDH7A1 metabolizes 4-HNE directly.\",\n      \"method\": \"Stable CHO cell transfection with viability assays, in vitro recombinant enzyme activity assays with oxidant treatment and β-mercaptoethanol rescue\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro enzyme assay plus cell-based functional assays in single lab, two orthogonal methods\",\n      \"pmids\": [\"21338592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALDH7A1 enzymatic activity generates NADH from NAD+; this NADH product targets BARS (Brefeldin-A ADP-Ribosylated Substrate) to inhibit COPI vesicle fission, thereby broadly inhibiting intracellular transport pathways. During hypoxia and starvation, this transport inhibition reduces energy consumption to promote cellular energy homeostasis.\",\n      \"method\": \"Biochemical assays of COPI vesicle formation, NADH measurement, BARS interaction studies, knockdown/overexpression experiments, energy consumption assays under hypoxia/starvation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic pathway established with multiple orthogonal assays (biochemical reconstitution of COPI inhibition, NADH measurement, genetic manipulation with defined metabolic phenotype)\",\n      \"pmids\": [\"31492851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ALDH7A1 protects against ferroptosis through two mechanisms: (1) its dehydrogenase activity generates NADH on cellular membranes, which supports FSP1 (ferroptosis suppressor protein 1) activity to reduce lipid peroxidation; (2) it directly consumes reactive aldehydes to decrease lipid peroxidation. Under ferroptotic stress, AMPK is activated and promotes membrane localization of ALDH7A1, which in turn stabilizes FSP1 on membranes.\",\n      \"method\": \"NADH localization assays, FSP1 activity assays, AMPK activation/inhibition experiments, membrane fractionation, ALDH7A1 knockdown/overexpression with ferroptosis readouts, lipid peroxidation assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal mechanistic methods (enzymatic assays, membrane fractionation, genetic manipulation, pathway epistasis via AMPK), published in high-tier journal with rigorous controls\",\n      \"pmids\": [\"40233740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Aldh7a1-null zebrafish (generated by CRISPR-Cas9) display spontaneous recurrent seizures with epileptiform electrographic activity, impaired lysine degradation with accumulation of PDE biomarkers (α-AASA, P6C, pipecolic acid), B6 deficiency, and reduced GABA levels. Seizures are rescued by pyridoxine/pyridoxal 5'-phosphate, and lysine supplementation aggravates the phenotype.\",\n      \"method\": \"CRISPR-Cas9 knockout zebrafish, electroencephalography (tectal recordings), LC-MS/MS metabolite quantification, behavioral assays, pharmacological rescue experiments\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knockout model with multiple biochemical and electrophysiological readouts, replicated by independent CRISPR zebrafish study (PMID 29053735)\",\n      \"pmids\": [\"29061647\", \"29053735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Human antiquitin (ATQ1/ALDH7A1) is expressed in cochlear outer hair cells (detected by RT-PCR of rat hair cell-specific cDNA), as well as highly in human fetal cochlea, ovary, eye, heart, and kidney. The gene was mapped to human chromosome 5q31 by FISH and mouse chromosome 18 by SSCP mapping.\",\n      \"method\": \"Northern blot of 13 human fetal tissues, RT-PCR of rat cochlear hair cell-specific cDNA libraries, FISH, SSCP mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct localization by RT-PCR and Northern blot with tissue specificity established, chromosomal mapping confirmed by two methods\",\n      \"pmids\": [\"9417906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Morpholino knockdown of aldh7a1 in zebrafish causes uveal coloboma and skeletal abnormalities, with reduced cell proliferation in the optic cup. The coloboma phenotype is associated with misregulation of nlz1 (a known coloboma gene), and is partially rescued by co-injection of nlz1 mRNA, placing nlz1 functionally downstream of aldh7a1 in regulating optic cup cell proliferation.\",\n      \"method\": \"Morpholino knockdown in zebrafish, phenotypic scoring, cell proliferation assays, gene expression analysis, mRNA rescue experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific developmental phenotype and partial pathway epistasis via rescue experiment, single lab\",\n      \"pmids\": [\"25004007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ALDH7A1 encodes α-aminoadipic semialdehyde dehydrogenase (antiquitin), which converts α-aminoadipic semialdehyde (α-AASA) into α-aminoadipic acid (AAA) as a critical step in brain lysine catabolism. ALDH7A1 dysfunction causes accumulation of α-AASA and P6C; P6C binds and inactivates PLP (the active form of vitamin B6). A novel missense mutation (c.566G>A, p.Gly189Glu) in the NAD+ binding domain of exon 6 was shown to cause neonatal PDE.\",\n      \"method\": \"Sequence analysis, clinical biochemistry, mutation characterization\",\n      \"journal\": \"Molecular and cellular probes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — mutational and biochemical characterization replicated across multiple clinical studies; mechanistic detail of P6C-PLP condensation established in earlier work\",\n      \"pmids\": [\"27856333\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ALDH7A1 (antiquitin) is a NAD+-dependent aldehyde dehydrogenase localized in the cytosol, nucleus, and mitochondria that catalyzes the oxidation of α-aminoadipic semialdehyde (the rate-limiting step in brain lysine catabolism), betaine aldehyde (generating the osmolyte betaine), and lipid peroxidation-derived aldehydes (e.g., 4-HNE); loss-of-function mutations cause pyridoxine-dependent epilepsy by allowing accumulation of piperideine-6-carboxylate, which inactivates pyridoxal phosphate via Knoevenagel condensation; additionally, the NADH generated by ALDH7A1 activity supports FSP1-mediated ferroptosis suppression on cellular membranes and inhibits COPI-mediated intracellular transport via BARS to conserve energy during hypoxia/starvation, with AMPK-dependent membrane recruitment of ALDH7A1 further stabilizing FSP1 under ferroptotic stress.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ALDH7A1 (antiquitin) is an NAD+-dependent aldehyde dehydrogenase that operates at the intersection of amino acid catabolism, osmotic and oxidative stress defense, and cellular energy homeostasis [#0]. It catalyzes the oxidation of α-aminoadipic semialdehyde (α-AASA) — the critical step in brain lysine degradation that produces α-aminoadipic acid — as well as betaine aldehyde (generating the osmolyte betaine) and lipid peroxidation-derived aldehydes such as 4-HNE, and its expression protects cells from osmotic and aldehyde/oxidant cytotoxicity [#0, #2]. Loss-of-function mutations in ALDH7A1 cause pyridoxine-dependent epilepsy: impaired α-AASA dehydrogenation allows accumulation of piperideine-6-carboxylate (P6C), which inactivates pyridoxal 5'-phosphate by Knoevenagel condensation, producing secondary vitamin B6 deficiency and seizures [#1, #8]. This disease mechanism is recapitulated in Aldh7a1-null zebrafish, which show recurrent seizures, PDE biomarker accumulation, reduced GABA, and rescue by pyridoxine/PLP [#5]. Beyond aldehyde clearance, the NADH product of ALDH7A1 acts as a signaling/metabolic output: it inhibits BARS-dependent COPI vesicle fission to suppress intracellular transport and conserve energy during hypoxia and starvation [#3], and it supports FSP1-mediated suppression of ferroptosis on cellular membranes, with AMPK-driven membrane recruitment of ALDH7A1 stabilizing FSP1 under ferroptotic stress [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that antiquitin/ALDH7A1 is a tissue-specifically expressed gene and mapped it to a defined chromosomal locus, providing the molecular handle for later functional and disease work.\",\n      \"evidence\": \"Northern blot of human fetal tissues, RT-PCR of cochlear hair cell cDNA, FISH and SSCP chromosomal mapping\",\n      \"pmids\": [\"9417906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No enzymatic activity or substrate assigned at this stage\", \"Functional role in any tissue undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved why ALDH7A1 mutations cause disease, linking loss of α-AASA dehydrogenase activity to PLP inactivation and seizures rather than a vague metabolic defect.\",\n      \"evidence\": \"Mutational analysis in 18 patients with biochemical measurement of pipecolic acid and α-AASA and clinical correlation\",\n      \"pmids\": [\"17068770\", \"20554659\", \"19128417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"P6C–PLP Knoevenagel condensation inferred biochemically rather than structurally resolved in vivo\", \"Did not define the enzyme's full substrate repertoire\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the enzyme's biochemical identity and substrate breadth, showing ALDH7A1 oxidizes α-AASA, betaine aldehyde, and lipid-peroxidation aldehydes and links to osmotic stress protection.\",\n      \"evidence\": \"Recombinant enzyme assays, crystal structure, stable CHO expression with viability assays, and subcellular fractionation\",\n      \"pmids\": [\"20207735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of multi-organelle (cytosol/nucleus/mitochondria) localization not dissected\", \"Relative in vivo flux through each substrate unquantified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated a cytoprotective antioxidant role, showing mitochondrial ALDH7A1 detoxifies reactive aldehydes and is itself redox-regulated through oxidative inactivation/reactivation.\",\n      \"evidence\": \"Stable CHO transfection viability assays and in vitro enzyme assays with oxidant treatment and β-mercaptoethanol rescue\",\n      \"pmids\": [\"21338592\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell model; in vivo antioxidant contribution not established\", \"Physiological redox switch mechanism not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Implicated ALDH7A1 in eye/skeletal development beyond metabolism, placing nlz1 functionally downstream in optic cup proliferation.\",\n      \"evidence\": \"Morpholino knockdown in zebrafish with phenotypic scoring, proliferation assays, and nlz1 mRNA rescue\",\n      \"pmids\": [\"25004007\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Morpholino-based; not confirmed by stable genetic knockout\", \"Molecular link between ALDH7A1 enzymatic activity and nlz1 regulation unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided an in vivo genetic model confirming the lysine-catabolism/B6-deficiency seizure mechanism and demonstrating pharmacological rescue.\",\n      \"evidence\": \"CRISPR-Cas9 knockout zebrafish with EEG, LC-MS/MS metabolite quantification, behavioral assays, and pyridoxine/PLP rescue; replicated by an independent CRISPR study\",\n      \"pmids\": [\"29061647\", \"29053735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address non-metabolic ALDH7A1 functions\", \"Mechanism of GABA reduction downstream of PLP deficiency not fully traced\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a signaling role for the enzyme's NADH product, connecting ALDH7A1 activity to suppression of COPI vesicle fission and energy conservation under nutrient/oxygen limitation.\",\n      \"evidence\": \"COPI vesicle formation assays, NADH measurement, BARS interaction studies, and genetic manipulation with energy-consumption readouts under hypoxia/starvation\",\n      \"pmids\": [\"31492851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural basis of NADH–BARS regulation not resolved\", \"Tissue/physiological contexts where this pathway dominates unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended the NADH-output paradigm to ferroptosis defense, showing AMPK-driven membrane recruitment of ALDH7A1 supports and stabilizes FSP1 while direct aldehyde clearance lowers lipid peroxidation.\",\n      \"evidence\": \"NADH localization and FSP1 activity assays, AMPK activation/inhibition, membrane fractionation, and ALDH7A1 perturbation with ferroptosis/lipid peroxidation readouts\",\n      \"pmids\": [\"40233740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of AMPK-dependent membrane targeting of ALDH7A1 not molecularly defined\", \"Relative contribution of NADH-FSP1 axis versus direct aldehyde consumption not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ALDH7A1's distinct activities — lysine catabolism, osmolyte/aldehyde detoxification, NADH-driven COPI inhibition, and ferroptosis suppression — are coordinated and partitioned across its cytosolic, nuclear, mitochondrial, and membrane pools remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No integrated model linking subcellular localization to specific functional output\", \"Whether the developmental (coloboma) phenotype reflects metabolic or NADH-signaling functions is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:1430728\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 3, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BARS\", \"FSP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}